Government Clarifies No Blanket Ban on Dextromethorphan Amid Cough Syrup Controversy

India’s Press Information Bureau (PIB) fact-check division has debunked misleading claims about a complete ban on Dextromethorphan Hydrobromide in cough syrups, amid growing concerns following the recent deaths of children in Madhya Pradesh.

The PIB clarification comes in response to a viral social media video suggesting the chemical component was banned but continued to be used in medications. Government officials emphasized that no blanket prohibition exists on the substance, which is a common ingredient in many cough suppressant formulations.

“The Central Drugs Standard Control Organisation has only banned specific fixed-dose combinations containing Dextromethorphan Hydrobromide when combined with antihistamines and decongestants,” the PIB stated. These restrictions primarily apply to pediatric use, with mandatory labeling requirements specifying “not for children below 4 years.”

The controversy emerges against the backdrop of a tragic situation in Madhya Pradesh, where approximately 20 children died from kidney failure after consuming contaminated cough syrup. Health authorities have linked these fatalities to a product marketed under the brand name Coldrif.

In response to the deaths, Indian regulators have banned three specific cough syrup brands: Coldrif, Respifresh TR, and ReLife. Laboratory analysis revealed these products contained dangerous levels of diethylene glycol (DEG), a toxic industrial solvent that can cause acute kidney injury when ingested.

“The contaminated syrups contained 48.6% diethylene glycol, which drastically exceeds the safety threshold of 0.1% established by both Indian regulations and World Health Organization guidelines,” explained a senior health official familiar with the investigation.

This isn’t the first time Indian pharmaceutical products have faced scrutiny over quality control issues. In recent years, multiple incidents involving contaminated medications have raised concerns about regulatory oversight in the country’s pharmaceutical sector, which ranks as one of the world’s largest exporters of generic medications.

Last week, the Directorate General of Health Services (DGHS) issued comprehensive guidelines on cough syrup administration, particularly for young children. The advisory explicitly states that cough medications “should not be prescribed or dispensed to children under 2 years” and “are generally not recommended for ages below 5 years.”

For older children, the DGHS recommends that any use “should follow careful clinical evaluation with close supervision and strict adherence to appropriate dosing, the shortest effective duration and avoiding multiple drug combinations.” The advisory also emphasized the importance of public education about following medical prescriptions.

Pediatric health experts have long cautioned against the overuse of cough suppressants in young children, noting that many common cold symptoms are better managed through supportive care rather than medication.

“The effectiveness of cough suppressants in young children has limited evidence, while the potential risks from improper dosing or contamination are significant,” said Dr. Aruna Sharma, a Delhi-based pediatrician. “Parents should consult healthcare providers before administering any cough medication to children.”

The pharmaceutical industry has faced increased regulatory scrutiny following these incidents, with calls for more rigorous testing protocols and enhanced quality control measures. Industry representatives have acknowledged the need for improved standards while noting that most manufacturers adhere to strict safety guidelines.

As investigations continue into the contaminated products, health authorities have urged vigilance from both medical professionals and the public regarding cough medications, particularly those intended for pediatric use.